JP2018520996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520996A5 JP2018520996A5 JP2017558454A JP2017558454A JP2018520996A5 JP 2018520996 A5 JP2018520996 A5 JP 2018520996A5 JP 2017558454 A JP2017558454 A JP 2017558454A JP 2017558454 A JP2017558454 A JP 2017558454A JP 2018520996 A5 JP2018520996 A5 JP 2018520996A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- expression level
- tumor sample
- patient
- binding antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 78
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 78
- 206010028980 Neoplasm Diseases 0.000 claims 76
- 230000014509 gene expression Effects 0.000 claims 48
- 238000000034 method Methods 0.000 claims 43
- 239000005557 antagonist Substances 0.000 claims 42
- 239000003814 drug Substances 0.000 claims 29
- 210000004881 tumor cell Anatomy 0.000 claims 17
- 210000002865 immune cell Anatomy 0.000 claims 16
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 14
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 14
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 7
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 6
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 238000003753 real-time PCR Methods 0.000 claims 6
- 108091006020 Fc-tagged proteins Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 230000008878 coupling Effects 0.000 claims 4
- 238000010168 coupling process Methods 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 4
- 229950009791 durvalumab Drugs 0.000 claims 4
- 238000003364 immunohistochemistry Methods 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 108020004999 messenger RNA Proteins 0.000 claims 4
- 229960003301 nivolumab Drugs 0.000 claims 4
- 102000008186 Collagen Human genes 0.000 claims 3
- 108010035532 Collagen Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229920001436 collagen Polymers 0.000 claims 3
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000945371 Homo sapiens Killer cell immunoglobulin-like receptor 2DL2 Proteins 0.000 claims 2
- 101000945333 Homo sapiens Killer cell immunoglobulin-like receptor 2DL3 Proteins 0.000 claims 2
- 101000945331 Homo sapiens Killer cell immunoglobulin-like receptor 2DL4 Proteins 0.000 claims 2
- 101000945339 Homo sapiens Killer cell immunoglobulin-like receptor 2DS2 Proteins 0.000 claims 2
- 101000945351 Homo sapiens Killer cell immunoglobulin-like receptor 3DL1 Proteins 0.000 claims 2
- 101001049181 Homo sapiens Killer cell lectin-like receptor subfamily B member 1 Proteins 0.000 claims 2
- 101000971538 Homo sapiens Killer cell lectin-like receptor subfamily F member 1 Proteins 0.000 claims 2
- 101000971533 Homo sapiens Killer cell lectin-like receptor subfamily G member 1 Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims 2
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 claims 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101001109470 Homo sapiens NKG2-E type II integral membrane protein Proteins 0.000 claims 2
- 101000589301 Homo sapiens Natural cytotoxicity triggering receptor 1 Proteins 0.000 claims 2
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 claims 2
- 108020003285 Isocitrate lyase Proteins 0.000 claims 2
- 102100033599 Killer cell immunoglobulin-like receptor 2DL2 Human genes 0.000 claims 2
- 102100033634 Killer cell immunoglobulin-like receptor 2DL3 Human genes 0.000 claims 2
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 claims 2
- 102100033630 Killer cell immunoglobulin-like receptor 2DS2 Human genes 0.000 claims 2
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 claims 2
- 102100023678 Killer cell lectin-like receptor subfamily B member 1 Human genes 0.000 claims 2
- 102100021458 Killer cell lectin-like receptor subfamily F member 1 Human genes 0.000 claims 2
- 102100021457 Killer cell lectin-like receptor subfamily G member 1 Human genes 0.000 claims 2
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims 2
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims 2
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 claims 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 claims 2
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 2
- 102100022701 NKG2-E type II integral membrane protein Human genes 0.000 claims 2
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims 2
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100028467 Perforin-1 Human genes 0.000 claims 2
- 238000003559 RNA-seq method Methods 0.000 claims 2
- 108010044012 STAT1 Transcription Factor Proteins 0.000 claims 2
- 102000006381 STAT1 Transcription Factor Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000002950 fibroblast Anatomy 0.000 claims 2
- 238000000684 flow cytometry Methods 0.000 claims 2
- 238000010166 immunofluorescence Methods 0.000 claims 2
- 238000007901 in situ hybridization Methods 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 239000010445 mica Substances 0.000 claims 2
- 229910052618 mica group Inorganic materials 0.000 claims 2
- 238000010208 microarray analysis Methods 0.000 claims 2
- 210000000651 myofibroblast Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 238000010839 reverse transcription Methods 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 229950007213 spartalizumab Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000001262 western blot Methods 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 238000003860 storage Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022013871A JP7534344B2 (ja) | 2015-05-12 | 2022-02-01 | 癌のための治療方法及び診断方法 |
| JP2024125652A JP2024170394A (ja) | 2015-05-12 | 2024-08-01 | 癌のための治療方法及び診断方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562160561P | 2015-05-12 | 2015-05-12 | |
| US62/160,561 | 2015-05-12 | ||
| US201562168700P | 2015-05-29 | 2015-05-29 | |
| US62/168,700 | 2015-05-29 | ||
| PCT/US2016/032112 WO2016183326A1 (en) | 2015-05-12 | 2016-05-12 | Therapeutic and diagnostic methods for cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013871A Division JP7534344B2 (ja) | 2015-05-12 | 2022-02-01 | 癌のための治療方法及び診断方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520996A JP2018520996A (ja) | 2018-08-02 |
| JP2018520996A5 true JP2018520996A5 (enExample) | 2019-06-13 |
| JP7048319B2 JP7048319B2 (ja) | 2022-04-05 |
Family
ID=56072467
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017558454A Active JP7048319B2 (ja) | 2015-05-12 | 2016-05-12 | 癌のための治療方法及び診断方法 |
| JP2022013871A Active JP7534344B2 (ja) | 2015-05-12 | 2022-02-01 | 癌のための治療方法及び診断方法 |
| JP2024125652A Pending JP2024170394A (ja) | 2015-05-12 | 2024-08-01 | 癌のための治療方法及び診断方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013871A Active JP7534344B2 (ja) | 2015-05-12 | 2022-02-01 | 癌のための治療方法及び診断方法 |
| JP2024125652A Pending JP2024170394A (ja) | 2015-05-12 | 2024-08-01 | 癌のための治療方法及び診断方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20180030138A1 (enExample) |
| EP (2) | EP3783029A1 (enExample) |
| JP (3) | JP7048319B2 (enExample) |
| KR (2) | KR20180008449A (enExample) |
| CN (3) | CN122238640A (enExample) |
| AU (2) | AU2016262074A1 (enExample) |
| CA (1) | CA2983282A1 (enExample) |
| DK (1) | DK3294770T4 (enExample) |
| ES (1) | ES2835866T5 (enExample) |
| FI (1) | FI3294770T4 (enExample) |
| HK (1) | HK1250376A1 (enExample) |
| HR (1) | HRP20201900T4 (enExample) |
| HU (1) | HUE051815T2 (enExample) |
| IL (2) | IL255312B (enExample) |
| LT (1) | LT3294770T (enExample) |
| MX (2) | MX2017014381A (enExample) |
| PL (1) | PL3294770T5 (enExample) |
| PT (1) | PT3294770T (enExample) |
| RS (1) | RS61152B2 (enExample) |
| SI (1) | SI3294770T2 (enExample) |
| WO (1) | WO2016183326A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| DK3294770T4 (da) | 2015-05-12 | 2024-05-21 | Hoffmann La Roche | Terapeutiske og diagnostiske fremgangsmåder til cancer |
| CN116726183A (zh) | 2015-08-03 | 2023-09-12 | Enb治疗公司 | 用于治疗与etbr激活相关的癌症的组合物和方法 |
| US10471055B2 (en) * | 2015-08-17 | 2019-11-12 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| BR112018011029A2 (pt) | 2016-01-08 | 2018-11-21 | Hoffmann La Roche | métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits |
| US20190376146A1 (en) * | 2016-11-24 | 2019-12-12 | Daiichi Sankyo Company, Limited | Method for predicting sensitivity of cancer to treatment with pd-1 immune checkpoint inhibitor |
| CN110198738A (zh) * | 2017-01-07 | 2019-09-03 | 默克专利有限公司 | 用于靶向的TGF-β抑制的给药方案和剂型 |
| MX2019008348A (es) * | 2017-01-18 | 2019-10-21 | Genentech Inc | Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas. |
| US20190360051A1 (en) * | 2017-02-17 | 2019-11-28 | Stichting Vumc | Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets |
| CN117442719A (zh) * | 2017-02-21 | 2024-01-26 | 瑞泽恩制药公司 | 用于治疗肺癌的抗pd-1抗体 |
| WO2018160717A1 (en) * | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| MX2019010295A (es) | 2017-03-01 | 2019-11-21 | Genentech Inc | Métodos de diagnóstico y terapéuticos para el cáncer. |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| AU2018304458B2 (en) | 2017-07-21 | 2021-12-09 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
| US10269803B2 (en) * | 2017-08-31 | 2019-04-23 | Taiwan Semiconductor Manufacturing Company, Ltd. | Hybrid scheme for improved performance for P-type and N-type FinFETs |
| WO2019140324A1 (en) | 2018-01-12 | 2019-07-18 | Enb Therapeutics, Inc. | Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation |
| EP3752528A4 (en) * | 2018-02-17 | 2021-11-03 | Apollomics Inc. | CANCER TREATMENT USING A COMBINATION OF A NEUTROPHIL MODULATOR WITH AN IMMUNE CHECKPOINT MODULATOR |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| WO2019207030A1 (en) * | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer |
| US20210363590A1 (en) * | 2018-05-21 | 2021-11-25 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
| EP3823611A1 (en) * | 2018-07-18 | 2021-05-26 | Genentech, Inc. | Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent |
| KR102084196B1 (ko) * | 2018-08-29 | 2020-03-03 | 연세대학교 산학협력단 | 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
| AU2019342133B8 (en) | 2018-09-21 | 2025-08-07 | Genentech, Inc. | Diagnostic methods for triple-negative breast cancer |
| EP3867646A1 (en) | 2018-10-18 | 2021-08-25 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| AU2020268885B2 (en) * | 2019-05-03 | 2026-06-11 | Cornell University | Markers for identifying and quantifying of nucleic acid sequence mutation, expression, splice variant, translocation, copy number, or methylation changes |
| CN111973739B (zh) * | 2019-05-23 | 2024-02-13 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| US20210030868A1 (en) * | 2019-07-29 | 2021-02-04 | Cai Gu Huang | Formulation of antibody based drugs for treating lung cancer by inhalation |
| EP3792632A1 (en) * | 2019-09-16 | 2021-03-17 | Vito NV | Immunotherapy markers |
| IL294800A (en) | 2020-01-27 | 2022-09-01 | Genentech Inc | Methods of treating cancer with an antibody to an anti-ti antagonist |
| CN115698717A (zh) * | 2020-04-03 | 2023-02-03 | 基因泰克公司 | 癌症的治疗和诊断方法 |
| WO2021224215A1 (en) * | 2020-05-05 | 2021-11-11 | F. Hoffmann-La Roche Ag | Predicting response to pd-1 axis inhibitors |
| WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
| EP4291897A1 (en) * | 2021-02-09 | 2023-12-20 | Institut National de la Santé et de la Recherche Médicale (INSERM) | New method to pronostic lung cancer |
| JP2024516230A (ja) | 2021-04-30 | 2024-04-12 | ジェネンテック， インコーポレイテッド | がんのための治療及び診断方法並びに組成物 |
| US20240336693A1 (en) * | 2021-08-10 | 2024-10-10 | Apexigen, Inc. | Biomarkers for cd40 agonist therapy |
| AU2023269154B2 (en) | 2022-05-12 | 2026-05-14 | Genentech, Inc. | Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist |
| JP2025523387A (ja) | 2022-06-07 | 2025-07-23 | ジェネンテック， インコーポレイテッド | 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法 |
| WO2024163009A1 (en) | 2023-01-31 | 2024-08-08 | Genentech, Inc. | Methods and compositions for treating urothelial bladder cancer |
| TW202436339A (zh) | 2023-01-31 | 2024-09-16 | 瑞士商赫孚孟拉羅股份公司 | 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途 |
| KR20250163916A (ko) | 2023-03-06 | 2025-11-21 | 제넨테크, 인크. | 비소세포 폐암의 예후 및 치료 방법 |
| TW202515614A (zh) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | 治療非小細胞肺癌之方法及組成物 |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
| CN122245790A (zh) * | 2026-05-21 | 2026-06-19 | 齐鲁工业大学(山东省科学院) | 基于知识引导和干预-响应驱动的血管炎症预测方法 |
Family Cites Families (144)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| JP2002506353A (ja) | 1997-06-24 | 2002-02-26 | ジェネンテック・インコーポレーテッド | ガラクトシル化糖タンパク質の方法及び組成物 |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| JP2003516755A (ja) | 1999-12-15 | 2003-05-20 | ジェネンテック・インコーポレーテッド | ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法 |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DE60131456T2 (de) | 2000-11-30 | 2008-07-10 | Medarex, Inc., Milpitas | Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern |
| EP1423510A4 (en) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| WO2003085102A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| EP1513879B1 (en) | 2002-06-03 | 2018-08-22 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| HUE035898T2 (en) | 2002-12-16 | 2018-05-28 | Genentech Inc | Immunoglobulin variants and their applications |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| US8219149B2 (en) | 2005-06-29 | 2012-07-10 | Nokia Corporation | Mobile communication terminal |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1957531B1 (en) | 2005-11-07 | 2016-04-13 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
| WO2007064919A2 (en) | 2005-12-02 | 2007-06-07 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010089411A2 (en) * | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| KR20150131269A (ko) * | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| AU2014275166B2 (en) * | 2013-06-06 | 2020-09-10 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms |
| IL321966A (en) | 2013-09-11 | 2025-09-01 | Medimmune Ltd | Anti-B7-H1 antibodies for tumor treatment |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| TW201614237A (en) | 2014-09-05 | 2016-04-16 | Medimmune Ltd | Markers for identifying patients responsive to anti-PD-L1 antibody therapy |
| EP3254110B1 (en) * | 2015-02-03 | 2020-03-18 | Ventana Medical Systems, Inc. | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
| DK3294770T4 (da) | 2015-05-12 | 2024-05-21 | Hoffmann La Roche | Terapeutiske og diagnostiske fremgangsmåder til cancer |
| EP4143345A1 (en) * | 2020-04-28 | 2023-03-08 | Genentech, Inc. | Methods and compositions for non-small cell lung cancer immunotherapy |
-
2016
- 2016-05-12 DK DK16724821.0T patent/DK3294770T4/da active
- 2016-05-12 LT LTEP16724821.0T patent/LT3294770T/lt unknown
- 2016-05-12 IL IL255312A patent/IL255312B/en unknown
- 2016-05-12 HU HUE16724821A patent/HUE051815T2/hu unknown
- 2016-05-12 IL IL295002A patent/IL295002A/en unknown
- 2016-05-12 EP EP20191243.3A patent/EP3783029A1/en active Pending
- 2016-05-12 ES ES16724821T patent/ES2835866T5/es active Active
- 2016-05-12 HR HRP20201900TT patent/HRP20201900T4/hr unknown
- 2016-05-12 HK HK18109832.3A patent/HK1250376A1/zh unknown
- 2016-05-12 FI FIEP16724821.0T patent/FI3294770T4/fi active
- 2016-05-12 CN CN202610251429.0A patent/CN122238640A/zh active Pending
- 2016-05-12 CN CN201680031772.9A patent/CN107667119A/zh active Pending
- 2016-05-12 MX MX2017014381A patent/MX2017014381A/es unknown
- 2016-05-12 KR KR1020177031945A patent/KR20180008449A/ko not_active Ceased
- 2016-05-12 CN CN202610251426.7A patent/CN122283131A/zh active Pending
- 2016-05-12 CA CA2983282A patent/CA2983282A1/en active Pending
- 2016-05-12 PL PL16724821.0T patent/PL3294770T5/pl unknown
- 2016-05-12 WO PCT/US2016/032112 patent/WO2016183326A1/en not_active Ceased
- 2016-05-12 SI SI201631013T patent/SI3294770T2/sl unknown
- 2016-05-12 PT PT167248210T patent/PT3294770T/pt unknown
- 2016-05-12 KR KR1020257003019A patent/KR20250021621A/ko active Pending
- 2016-05-12 JP JP2017558454A patent/JP7048319B2/ja active Active
- 2016-05-12 AU AU2016262074A patent/AU2016262074A1/en not_active Abandoned
- 2016-05-12 RS RS20201469A patent/RS61152B2/sr unknown
- 2016-05-12 EP EP16724821.0A patent/EP3294770B2/en active Active
-
2017
- 2017-10-19 US US15/787,988 patent/US20180030138A1/en not_active Abandoned
- 2017-11-09 MX MX2023002251A patent/MX2023002251A/es unknown
-
2021
- 2021-11-26 US US17/535,898 patent/US20220073623A1/en not_active Abandoned
-
2022
- 2022-02-01 JP JP2022013871A patent/JP7534344B2/ja active Active
- 2022-05-24 AU AU2022203501A patent/AU2022203501B2/en active Active
-
2024
- 2024-08-01 JP JP2024125652A patent/JP2024170394A/ja active Pending
-
2025
- 2025-08-29 US US19/314,084 patent/US20260055189A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521976A5 (enExample) | ||
| Herrera et al. | Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy | |
| JP2020513788A5 (enExample) | ||
| Rappaport et al. | A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results | |
| JP2019521641A5 (enExample) | ||
| Lu et al. | Current status and future perspective of immunotherapy in gastrointestinal cancers | |
| HRP20201900T1 (hr) | Terapeutski i dijagnostički postupci kod raka | |
| Dasgupta et al. | Inhibition of NK cell activity through TGF-β1 by down-regulation of NKG2D in a murine model of head and neck cancer | |
| JP2019515670A5 (enExample) | ||
| JP2019535237A5 (enExample) | ||
| AU2021277398A1 (en) | Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor | |
| JP2020516253A5 (enExample) | ||
| JP2017536842A5 (enExample) | ||
| García‐Carbonero et al. | Randomized phase II trial of parsatuzumab (anti‐EGFL7) or placebo in combination with FOLFOX and bevacizumab for first‐line metastatic colorectal cancer | |
| US20240110230A1 (en) | Biomarkers for cancer treatment | |
| JP2016520520A5 (enExample) | ||
| CN115087749A (zh) | 用于通过分析循环肿瘤dna进行分子疾病评定的方法和系统 | |
| CN114929267A (zh) | 使用靶向cd70的基因工程化t细胞的肾细胞癌（rcc）疗法 | |
| CN112442120A (zh) | 抗严重急性呼吸系统综合征ii型冠状病毒sars-cov-2的中和抗体 | |
| Iorgulescu et al. | Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model | |
| Borcoman et al. | Phase Ib/II trial of tipapkinogene sovacivec, a therapeutic human papillomavirus16-vaccine, in combination with avelumab in patients with advanced human papillomavirus16-positive cancers | |
| JP2020535119A5 (enExample) | ||
| CN114845729A (zh) | 使用靶向cd70的基因工程化t细胞的cd70+实体瘤疗法 | |
| Long et al. | Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial | |
| Shaik et al. | Tumor infiltration therapy: from FDA approval to next-generation approaches |